Novel macrophage targets for the treatment of atrial fibrillation
Nature Reviews Cardiology, Published online: 02 August 2023; doi:10.1038/s41569-023-00918-7A study shows that macrophages undergo substantial expansion in the diseased atria of patients with atrial fibrillation (AF), and identifies two potential immunotherapy targets for the treatment of AF. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - August 2, 2023 Category: Cardiology Authors: Karina Huynh Source Type: research
Cholesterol catabolism and bile acid synthesis in cardiomyocytes promote inflammation and heart failure
Nature Reviews Cardiology, Published online: 31 July 2023; doi:10.1038/s41569-023-00917-8In failing cardiomyocytes, depletion of carnitine acetyltransferase promotes cholesterol catabolism via the bile acid synthesis pathway. The intracellular accumulation of bile acid intermediates induces the release of mitochondrial DNA into the cytosol, triggering type I interferon responses and AIM2 inflammasome activation, thereby contributing to chronic myocardial inflammation and heart failure progression. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 31, 2023 Category: Cardiology Authors: Gregory B. Lim Source Type: research
Promising novel siRNA for the treatment of hypertension
Nature Reviews Cardiology, Published online: 31 July 2023; doi:10.1038/s41569-023-00916-9Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in serum angiotensinogen levels and 24-h ambulatory blood pressure that last for up to 24 weeks, according to a phase I study. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 31, 2023 Category: Cardiology Authors: Irene Fern ández-Ruiz Source Type: research
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals
Nature Reviews Cardiology, Published online: 26 July 2023; doi:10.1038/s41569-023-00912-zCardiovascular health is essential to achieving the United Nations Sustainable Development Goals (SDGs), particularly SDG3.4. Barriers include inequalities and a lack of political will and prioritization. A comprehensive approach is needed to reduce the global burden of cardiovascular disease and to achieve SDG3.4. The World Heart Federation addresses the determinants of cardiovascular disease and mobilizes the global community through roadmaps, roundtables and advocacy. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 26, 2023 Category: Cardiology Authors: Daniel J. Pi ñeiro Elisa Codato Jeremiah Mwangi Jean-Luc Eisel é Jagat Narula Source Type: research
Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping
Nature Reviews Cardiology, Published online: 25 July 2023; doi:10.1038/s41569-023-00915-wAccording to two papers from the OPTICO-ACS study, patients with acute coronary syndrome and an intact fibrous cap (plaque erosion), tend to have lower levels of inflammation and better prognosis than patients with rupture of the fibrous cap. In addition, Toll-like receptor 2-mediated neutrophil activation has a key role in plaque erosion. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 25, 2023 Category: Cardiology Authors: Jennifer Harman Source Type: research
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis
Nature Reviews Cardiology, Published online: 20 July 2023; doi:10.1038/s41569-023-00901-2Dual antiplatelet therapy (DAPT) reduces the risk of ischaemic events but can increase the risk of bleeding in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Gorog and colleagues provide consensus statements on strategies to reduce the risk of bleeding by de-escalating the intensity or abbreviating the duration of DAPT. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 20, 2023 Category: Cardiology Authors: Diana A. Gorog Jose Luis Ferreiro Ingo Ahrens Junya Ako Tobias Geisler Sigrun Halvorsen Kurt Huber Young-Hoon Jeong Eliano P. Navarese Andrea Rubboli Dirk Sibbing Jolanta M. Siller-Matula Robert F. Storey Jack W. C. Tan Jurrien M. ten Berg Marco Valgimigl Source Type: research
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries
Nature Reviews Cardiology, Published online: 18 July 2023; doi:10.1038/s41569-023-00900-3In this Roadmap, Föllmer et al. summarize the evidence for the application of artificial intelligence (AI) technology to the imaging of vulnerable plaques in coronary arteries and discuss the current and future approaches to addressing the limitations of AI-guided coronary plaque imaging, such as bias, uncertainty and generalizability. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 18, 2023 Category: Cardiology Authors: Bernhard F öllmer Michelle C. Williams Damini Dey Armin Arbab-Zadeh P ál Maurovich-Horvat Rick H. J. A. Volleberg Daniel Rueckert Julia A. Schnabel David E. Newby Marc R. Dweck Giulio Guagliumi Volkmar Falk Aldo J. V ázquez Mézquita Federico Biavati I Source Type: research
Heart transplantation: advances in expanding the donor pool and xenotransplantation
Nature Reviews Cardiology, Published online: 14 July 2023; doi:10.1038/s41569-023-00902-1Heart transplantation for patients with advanced heart failure is limited by a shortage of donor organs. In this Review, Jou and colleagues explore the options to increase the supply of donor hearts, including transplantation from donors with HCV, HIV or SARS-CoV-2 infection, national opt-out organ donation policies, donation after circulatory death, and xenotransplantation. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 14, 2023 Category: Cardiology Authors: Stephanie Jou Sean R. Mendez Jason Feinman Lindsey R. Mitrani Valentin Fuster Massimo Mangiola Nader Moazami Claudia Gidea Source Type: research
FGF23 and klotho at the intersection of kidney and cardiovascular disease
Nature Reviews Cardiology, Published online: 13 July 2023; doi:10.1038/s41569-023-00903-0In this Review, the authors present an overview of the role of fibroblast growth factor 23 (FGF23) and klotho in normal mineral homeostasis, discuss disordered mineral homeostasis in chronic kidney disease (CKD), and explore CKD-associated FGF23 excess and klotho deficiency as novel risk factors and potential therapeutic targets for cardiovascular disease. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 13, 2023 Category: Cardiology Authors: Daniel Edmonston Alexander Grabner Myles Wolf Source Type: research
RAPID return to sinus rhythm after SVT using intranasal etripamil
Nature Reviews Cardiology, Published online: 03 July 2023; doi:10.1038/s41569-023-00908-9In the multicentre, randomized, placebo-controlled RAPID trial, use of symptom-prompted, self-administered, intranasally delivered etripamil was safe and superior to placebo for the conversion of paroxysmal superventricular tachycardia to sinus rhythm. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 3, 2023 Category: Cardiology Authors: Karina Huynh Source Type: research
Ruxolitinib is a CaMKII inhibitor that can be repurposed to prevent arrhythmias
Nature Reviews Cardiology, Published online: 03 July 2023; doi:10.1038/s41569-023-00910-1The FDA-approved drug ruxolitinib has been identified as an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) that has the potential to be repurposed to treat arrhythmias induced by CaMKII hyperactivity. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - July 3, 2023 Category: Cardiology Authors: Karina Huynh Source Type: research
Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism
Nature Reviews Cardiology, Published online: 30 June 2023; doi:10.1038/s41569-023-00909-8Testosterone-replacement therapy in men with hypogonadism and a high risk of cardiovascular disease does not increase the risk of adverse cardiac events, according to data from the TRAVERSE trial. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - June 30, 2023 Category: Cardiology Authors: Gregory B. Lim Source Type: research
IL-6R antagonism ameliorates atherosclerosis linked to Tet2-related clonal haematopoiesis
Nature Reviews Cardiology, Published online: 26 June 2023; doi:10.1038/s41569-023-00907-wLiu and colleagues demonstrate the crucial role of IL-6 signalling in the development of atherosclerosis driven by Tet2-related clonal haematopoiesis. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - June 26, 2023 Category: Cardiology Authors: Karina Huynh Source Type: research
Low alcohol intake might lower CVD risk by reducing stress-related brain activity
Nature Reviews Cardiology, Published online: 26 June 2023; doi:10.1038/s41569-023-00906-xNew research shows that the reduced risk of major adverse cardiovascular events associated with light or moderate alcohol consumption is partly mediated by attenuation of the activity of a stress-related neural network. (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - June 26, 2023 Category: Cardiology Authors: Irene Fern ández-Ruiz Source Type: research
Author Correction: Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms
Nature Reviews Cardiology, Published online: 21 June 2023; doi:10.1038/s41569-023-00904-zAuthor Correction: Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms (Source: Nature Reviews Cardiology)
Source: Nature Reviews Cardiology - June 21, 2023 Category: Cardiology Authors: Stephane Heymans Leslie T. Cooper Source Type: research
